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SUMMARY
Evaluation of HIV vaccine candidates in non-human primates (NHPs) is a critical step toward
developing a successful vaccine to control the HIV pandemic. Historically, HIV vaccine regimens
have been tested in NHPs by administering a single high dose of the challenge virus. More recently,
evaluation of candidate HIV vaccines has entailed repeated low-dose challenges which more closely
mimic typical exposure in natural transmission settings. In this paper, we consider evaluation of the
type and magnitude of vaccine efficacy from such experiments. Based on the principal stratification
framework, we also address evaluation of potential immunological surrogate endpoints for infection.
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1 Introduction
As of 2007, approximately 33.2 million people were living infected with HIV, with over 2.1
million people dying of AIDS in that year (UNAIDS 2007). While great strides have been
made in developing effective antiretroviral therapy for treatment of HIV infected individuals,
a preventive vaccine remains the greatest hope in curbing the HIV pandemic. HIV vaccine
research begins with in vitro and animal studies. A critical component of this pre-clinical
development entails evaluation of candidate vaccines in non-human primates (NHPs) such as
macaques. Historically, HIV vaccine regimens have been tested in NHPs by administering a
single high dose of the challenge virus. More recently, evaluation of candidate HIV vaccines
has entailed repeated low-dose (RLD) challenges which more closely mimic typical exposure
to HIV in natural transmission settings (Regoes et al. 2005; Subbarao et al. 2006; Ellenberger
et al. 2006). A primary objective of these studies is to assess vaccine efficacy for prevention
of infection. A secondary objective is to determine immune biomarkers which are surrogate
endpoints for infection, which we refer to as “surrogates of protection.”
Since the RLD challenge study design has only recently been implemented in evaluation of
candidate HIV vaccines, the corresponding statistical literature is rather limited. One exception
is Regoes et al. (2005), who show that for clinically feasible samples sizes, RLD challenge
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studies in NHPs can be adequately powered to test for vaccine efficacy to prevent infection.
This rather surprising result is due to the exquisitely precise nature of the exposure and infection
history in challenge studies. In contrast, studies of HIV in humans typically provide only vague
information on the number of exposures prior to infection. Consequently RLD challenge
studies with small sample sizes can have the same power as large phase III clinical trials to test
for vaccine efficacy.
Beyond testing for a vaccine effect, it is not clear what additional information can be inferred
from RLD challenge studies. For example, can these studies inform about the type or magnitude
of a vaccine’s protective effect? Accurately characterizing the mechanism of protection would
provide important information for the design and analysis of future efficacy trials and for
population models on the impact of a licensed vaccine. Additionally, is it possible to evaluate
potential immune surrogates of protection in RLD challenge studies? This paper seeks to
answer these questions. In Section 2 we consider evaluating the type and magnitude of vaccine
efficacy from RLD challenge experiments; an illustrative example is given using recently
published results from a challenge study of a candidate HIV vaccine. In Section 3 we describe
a causal inference approach to assessing potential immunological surrogates of protection in
this setting. We conclude with a discussion in Section 4. Similar to Regoes et al. (2005), we
find that, despite relatively small sample sizes, RLD challenge studies can provide accurate
and precise information about vaccine efficacy and immune surrogate markers. While this work
is motivated by the development of an HIV vaccine, the proposed methods can easily be applied
to RLD challenge studies of other vaccines and other preventive interventions.
2 Vaccine efficacy for susceptibility
In this section we consider evaluating the type and magnitude of vaccine efficacy for
susceptibility (VES), i.e., a vaccine’s ability to protect against infection. Our approach entails
applying maximum likelihood methods to a discrete time survival model which allows for
possible heterogeneous vaccine effects (Halloran et al. 1992; Longini and Halloran 1996).
2.1 Discrete time survival model
Let p denote the probability of transmission to a susceptible, unvaccinated individual given a
single exposure (i.e., challenge). Assuming the probability of infection is independent of the
number of prior challenges, the probability of escaping infection from t challenges for an
unvaccinated individual is (1 − p)t. On the other hand, the probability an unvaccinated
individual becomes infected on the tth challenge is (1−p)t−1p. Next suppose a vaccine may
confer partial or complete protection to individuals. Let θ be the probability a vaccinated
individual is completely protected. Further, suppose the probability a vaccinated individual
who is not completely protected gets infected from a single challenge is φp. Then the probability
a vaccinated individual escapes infection from t challenges is (1 − φp)t(1 − θ) + θ, whereas the
probability a vaccinated individual becomes infected from challenge t is (1 − φp)t−1φp(1 − θ).
Since the probability a vaccinated individual becomes infected from a single challenge is (1 −
θ)φp, define the vaccine efficacy as
(1)
i.e., the relative reduction in the per contact transmission probability if vaccinated compared
to if not vaccinated. This measure of vaccine efficacy has been referred to as the per contact
or biological efficacy (Halloran et al. 1999). If θ > 0 and φ = 1, then each vaccinated individual
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is either completely protected or not at all protected. In this case the vaccine is said to have an
“all-or-none” effect with VES = θ. On the other hand, if θ = 0 and φ < 1, then only partial
protection is conferred to all vaccinees whereby each vaccinated individual has a reduced
transmission probability by the same multiplicative factor. In this case the vaccine is said to
have a “leaky” effect with VES = 1 − φ. If θ > 0 and φ ≠ 1, the vaccine has a “mixed” effect
with both all-or-none and leaky mechanisms of protection with efficacy (1). Finally, if θ = 0
and φ = 1, then the vaccine has no efficacy, i.e., VES = 0; we refer to this situation as the “null”
model.
Maximum likelihood methods (see Web Appendix A) can be employed for inference regarding
(p, θ, φ) based on data from a NHP challenge study such as described below in Section 2.2.
For such a study, we consider point and interval estimation of VES, as well as model selection
from among the four mechanism of protection models described above. While it is difficult to
discern a vaccine’s protective mechanism from a large human vaccine efficacy trial (Farrington
1998; Gilbert 2001), it is more feasible in an RLD challenge study, due to the far greater
information on exposure and transmission.
2.2 Example
Ellenberger et al. (2006) employed a RLD challenge study in macaques to assess the efficacy
of a candidate HIV vaccine. The vaccine was given to 16 macaques and 14 additional macaques
served as controls, i.e., did not receive the vaccine. All animals were then repeatedly exposed
weekly to a hybrid simian-human immunodefficiency virus (SHIV) with a different HIV
sequence than the HIV sequence represented in the vaccine. Evidence of systemic infection
was assessed after each exposure. Infection was defined as having detectable cell-free virus
and provirus in peripheral blood mononuclear cells. It is assumed that the cell-free and cell-
associated diagnostic tests used for infection diagnosis were sufficiently accurate and the
weekly time intervals between challenges were far enough apart such that determination of the
infecting exposure was made without error. Four monkeys in the vaccine arm and one in the
control arm were administratively right censored after escaping infection from multiple
exposures.
Data from this experiment are given in Web Table 1 and the corresponding maximum
likelihood results are given in Table 1. Based on a likelihood ratio test (LRT) comparing the
leaky and null models, there is evidence of a significant leaky vaccine effect (p-value=0.003).
A one-sided Fisher’s exact test (Regoes et al. 2005) gives a similar result (p-value=0.006).
Comparison of the log likelihood values for the leaky and all-or-none models suggests the
leaky model demonstrates superior fit. Similarly, the LRT comparing the mixed and leaky
models is not significant (p-value=0.2). The Akaike Information Criterion (AIC) also suggests
the leaky model provides the most parsimonious model that adequately fits the given data.
The Kaplan-Meier estimates of the survival function for each arm of the study are given in the
left panel of Figure 1. The agreement between these nonparametric estimates and the
corresponding estimates from the leaky vaccine model evaluated at the MLEs φ ̂ = 0.36 and p̂
= 0.20 suggest good fit of this model to the data. The nonparametric estimates of the
complementary log-log survival curves in the right panel of Figure 1 are roughly parallel, also
supporting a leaky vaccine effect (Halloran et al. 1999). To evaluate the mechanism of
protection further, simulated data sets were generated from the four different models under
consideration (evaluated at the MLEs from Table 1) to provide a basis of comparison. Figure
2 shows the difference in the non-parametric estimates of the complementary log-log survival
curves from the observed data and 25 simulated data sets from the four models. These plots
also suggest the leaky model provides a better fit than the all-or-none or null models.
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To formally test for goodness-of-fit, the following Kolmogorov-Smirnov type test statistic was
computed:
where  and  denote the survival curves for controls and vaccinees under the leaky
model when p = 0.20 and φ = 0.36, and Ŝc(t) and Ŝv(t) are the corresponding nonparametric
estimates. The sampling distribution of TKS was approximated by simulating 10,000 data sets
under the null hypothesis p = 0.20, φ = 0.36, and θ = 0. The resulting approximate p-value was
0.35, indicating adequate fit of the leaky model.
In total, these results suggest a significant leaky vaccine effect. The MLE of VES is 0.64, which
can be interpreted as a 64% reduction in the probability of infection per exposure. The Jewell
(1986) (see also Chick et al. 2001) bias corrected estimate of VES is 0.66. The profile likelihood
95% confidence interval (CI) for VES is (0.26, 0.83).
2.3 Simulation studies
Simulation studies were conducted to investigate the operating characteristics of several of the
statistical methods employed in the example above. Unless stated otherwise, data were
simulated assuming a transmission probability under control of p = 0.2, an equal number of
NHPs in the vaccine and control arms, and the experiment ceases after 20 exposures if a NHP
is still SHIV negative.
The first set of simulations assumed a leaky mechanism of protection, i.e., θ = 0. Based on
10,000 simulations, the power of the LRT comparing the leaky and null models to detect a
departure from the null hypothesis H0:φ = 1 at the α = 0.1 level is given in the top half of Table
2. For purposes of comparison with the power to detect an all-or-none effect (discussed below),
here we assumed φ ≤ 1, i.e., the vaccine does not increase the probability of infection per
exposure in individuals who are not complete protected. Consequently, since φ is on the
boundary of the parameter space under H0, the distribution of the LRT statistic was assumed
to be , i.e., a 50:50 mixture of chi-squared distributions with 0 and 1 degrees of
freedom (Self and Liang 1987). The results of Table 2 suggest the LRT preserves the type I
error for sample sizes typical of challenge studies and that the Ellenberger et al. (2006)
experiment had over 80% power to detect a leaky VES of 60%. Similar results were found
using a Wald test (results not shown). These findings are in agreement with Regoes et al.
(2005), who also showed low-dose challenge studies can be adequately powered to detect leaky
vaccine effects.
The second set of simulations assumed an all-or-none mechanism of protection, i.e., φ = 1. The
simulation results in the lower portion of Table 2 give the power for comparing the all-or-none
and null models to detect a departure from the null H0:θ = 0. Again the distribution of the LRT
statistic was assumed to be . Comparison of the upper and lower portions of Table
2 indicates there is greater power to detect an all-or-none effect than a leaky effect. Additional
simulations (results not shown) indicate the LRT also preserves the type I error rate when
comparing the mixture and leaky models.
A simulation study was also employed to assess the ability of the AIC to select the correct
mechanism of protection model (i.e., null, all-or-none, leaky, or mixed). The results in Web
Table 2 give the probability of selecting the correct model for different values of p, θ, φ, and
the maximum number of allowable challenges Cmax. If the true model is all-or-none or null,
the probability of selection is typically adequate, i.e., approximately 0.9. Correct selection can
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be substantially less likely for leaky or mixture models. For example, if p = 0.2 and Cmax = 30,
there is only a 0.01 probability of correctly selecting a mixture model when θ = 0.8 and φ =
0.2. However, by increasing p to 0.5 (e.g., by increasing the challenge dose) or increasing
Cmax, the probability of correct selection for leaky and mixture models increases. Nonetheless,
these results indicate model selection should not be based on AIC alone in this setting.
Finally, we also examined the bias of the MLE of VES under the leaky model. Simulation
results in Web Table 3 demonstrate an appreciable negative bias of  for smaller sample
sizes. The Jewell bias corrected estimator (Jewell 1986;Chick et al. 2001) appears to be
preferable in terms of bias; Chick et al. (2001) reached a similar conclusion in the context of
vaccine efficacy evaluation in small or intermediate size (e.g., Phase IIb) clinical trials. For
each simulated data set, we also computed a profile likelihood 95% CI for VES. The empirical
coverage probability of these CIs given in Web Table 3 is very close to the nominal coverage
probability.
2.4 Elaborations
2.4.1 Accommodating heterogeneous transmission probabilities—To this point
we have assumed a homogeneous transmission probability p, i.e., that every individual has the
same natural susceptibility to infection at each time point. This assumption may be violated
due to among-individual variability in host genetics (e.g., HLA type), immunity, and other
characteristics. Failing to account for susceptibility heterogeneity may lead to biased estimation
of VES and to undercoverage of confidence intervals (Halloran et al. 1992). To relax this
homogeneity assumption, we suppose the transmission probabilities vary between NHPs
according to a beta distribution. For the control group, the beta distribution of the transmission
probability p can be specified by the mean μ and coefficient of variation η. For the vaccine
subgroup not completely protected, we suppose the beta distribution of the transmission
probability, say pv, has mean φμ and coefficient of variation η. That is, the beta distributions
for the control and vaccine transmission probabilities are assumed to have the same coefficient
of variation but possibly different means. The vaccine efficacy estimand VES then takes the
same form as in (1), with modified interpretation as the percent change in the expected per-
contact transmission probability. Under the additional assumptions that the transmission
probabilities are independent across exposures within animals and the individual-specific mean
transmission probabilities have a beta distribution across individuals, then the assumption that
p and pv are constant across exposures within individuals is no longer needed (Weinberg and
Gladen 1986).
For each of the mixture, leaky, all-or-none, and null models, the MLE of (θ, φ, μ, η), and thus
of VES, can be computed using the likelihood given in the Web Appendix A. Returning to the
RLD challenge study in Section 2.2, maximum likelihood results allowing for heterogeneous
transmission probabilities are given in Web Table 4. Comparing these results with Table 1, the
AIC still selects a leaky vaccine model with homogeneous transmission probabilities.
2.4.2 A generalized estimand—The definition of vaccine efficacy given in (1) is based
on a single contact. More generally, VES could be defined in terms of t contacts for t ≥ 1, i.e.,
the relative reduction in the probability of infection from t exposures under vaccine compared
to control. If the vaccine is tested or to be used in a low-risk population, then the estimand
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VES(1)=VES might be considered. Conversely if the vaccine is tested in a high-risk population,
a definition with more exposures, for example VES(50), might be more appropriate. Plots of
VES(t) given in Web Figure 1 demonstrate the well known result that vaccine efficacy is not
affected by the number of exposures for an all-or-none mechanism model, whereas with a leaky
or mixed model, the efficacy decreases with an increasing number of exposures (Smith et al.
1984). Web Figure 1 also shows that the greater the transmission probability p, the greater the
attenuation effect.
The generalized definition VES(t) helps explain the greater observed power (Table 2) for
detecting an all-or-none effect compared to a leaky effect. For example, under the leaky model
with φ = 0.5, the alternative hypothesis is equivalent to {VES(t):θ = 0, φ = 0.5, t ≥ 1}, where
VES(t) is near 0 for t large. In contrast, for the all-or-none model with θ = 0.5, the alternative
hypothesis is equivalent to {VES(t):θ = 0.5, φ = 1, t ≥1}, where VES(t) = 0.5 for all t. Thus the
alternative for the all-or-none model can be viewed as farther from the null hypothesis than
the leaky model.
3 Surrogates of protection
In this section we present an approach for assessing potential immunological surrogates of
protection (SoP) in a RLD challenge study. In general, a SoP is defined to be an immunological
variable S such that a vaccine effect on S is predictive of a vaccine effect on the risk of infection
or disease (i.e., is predictive of VES). The utility of such a surrogate marker includes guiding
vaccine development, improving immunogens iteratively between basic and clinical research,
providing guidance for regulatory decisions, bridging efficacy of a vaccine observed in a trial
to a new setting, and guiding public immunization policy. For RLD challenge studies,
knowledge of an immunological surrogate may allow insightful and cost-effective comparisons
of vaccine candidates in animals, support predictions of vaccine efficacy in humans, and inform
prioritizing the most promising candidates for testing in humans.
Despite the importance of finding SoPs, the literature on methods for their quantitative
assessment is quite limited. Most existing approaches simply assess correlates of risk (CoRs),
i.e., immunological biomarkers that are associated with risk of infection or disease. For
example, in the first phase III trial of an HIV vaccine (VAX004), a significant negative
association was found between risk of HIV infection and antibody (Ab) response to the vaccine
(Gilbert et al. 2005). However, this purely correlational analysis provides no information to
distinguish between the possible explanations that (i) a greater vaccine effect on the immune
response predicted a greater vaccine effect on infection risk, or (ii) the immune response simply
marked an innate ability to escape infection but did not predict vaccine efficacy. In other words,
it was not possible to conclude whether Ab response to the vaccine was a SoP or just a CoR.
Qin et al. (2007) defined a hierarchy of two levels of SoPs: a specific SoP is predictive of
VES for the same setting (population, environmental factors) as present in the particular study,
and a general SoP is a specific SoP that is also predictive of VES across different settings (e.g.,
across populations or across vaccine formulations). Meta-analysis of multiple vaccine studies
is required for evaluating a general SoP whereas one study may be sufficient for evaluating a
specific SoP. While developing a general SoP is most valuable scientifically, developing a
specific SoP is valuable in itself and as an intermediate step toward developing a general SoP.
Moreover, enabling the evaluation of a general SoP is practically challenging, requiring several
vaccine studies that provide ample variability in the meta-analytic unit of interest, whereas a
specific SoP may be evaluated using a practicable augmentation of existing and planned
vaccine studies. Here we restrict attention to the evaluation of a specific SoP from a single
RLD challenge study of a candidate HIV vaccine.
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Recently, novel experimental designs and corresponding statistical methodology have been
proposed for evaluating potential specific SoPs in the context of human efficacy trials
(Follmann 2006; Gilbert and Hudgens 2008). Here we consider one of two designs proposed
by Follmann (2006) wherein for each individual we measure a baseline covariate(s) W that is
correlated with the immune response that individual would have to the HIV vaccine being
evaluated. For example, W might be an immune response to a rabies vaccine. The missing HIV
vaccine immune response for individuals in the control arm can then be predicted from their
W and a prediction model based on observed data from the vaccine group. In turn, we can
assess how well causal treatment effects on the HIV immune response predict the causal effect
of the vaccine to prevent infection. Simulation studies of large (e.g., Phase III) randomized
studies have demonstrated that the additional information provided by W can enable assessing
the extent to which a CoR is a SoP (Follmann 2006; Gilbert and Hudgens 2008). Below we
consider whether measuring a baseline predictor W in RLD challenge studies might also afford
sufficient information for inference regarding possible SoPs. We know of no RLD challenge
studies to date which have implemented Follmann’s baseline predictor study design.
3.1 Methods
Motivated by Ellenberger et al. (2006), we consider assessment of possible SoPs assuming a
leaky vaccine effect. We begin by introducing the potential outcomes notation to be used for
the SoP model. For subject i, let Ti(Z) be the potential survival time under assignment to
treatment Z for Z = 0 (control) or Z = 1 (vaccine). We assume throughout that survival time is
measured by the number of exposures (i.e., challenges) until infection; thus Ti(Z) is a positive
integer. Next let Si(Z) denote the HIV-specific immune response under treatment Z. We assume
Si(0) = 0 for all i since vaccine antigens (absent in the control) must be present to induce an
HIV-specific immune response. We also assume Si(1) ≥ 0 and that Si(1) is measured at a single
time point after treatment assignment and before the first exposure.
In order to identify the causal estimands of interest defined below, we invoke the stable unit
treatment value assumption (SUTVA) and assume ignorable treatment assignment. The lack
of interference between NHPs implied by SUTVA should hold in this setting since investigators
can prevent interaction between NHPs. Use of randomization in assigning NHPs to receive
vaccine or serve as a control will insure ignorable treatment assignment. In the context of
human vaccine trials, Gilbert and Hudgens (2008) make the additional assumption that the risk
of infection prior to measurement of Si is the same for Z = 0 and Z = 1. This additional
assumption is not required in RLD challenge studies since investigators control the timing of
exposures.
The average causal effect of the vaccine on survival is defined as h(E{Ti(0)}, E{Ti(1)}) where
h is some contrast function such that h(x, y) = 0 iff x = y, e.g., h(x, y) = x − y. Next let p(Z)
denote the probability of infection from a single exposure (i.e., the transmission probability)
under assignment to treatment Z. Assuming the probability of infection is independent of the
number of prior exposures, Ti(Z) has a geometric distribution with mean E{Ti(Z)} = 1/p(Z) for
Z = 0, 1, indicating the average causal effect can equivalently be described by a contrast in
transmission probabilities. For example, if h(x, y) = 1 − x/y, then the causal effect of the vaccine
on survival equals , which is equivalent to (1) (i.e., ) in the
absence of an all-or-none vaccine effect.
Next consider the principal stratification (Frangakis and Rubin 2002) of individuals according
to the pair of potential immune responses (Si(0), Si(1)). Since Si(0) = 0 for all i, membership
within a principal stratum is determined completely by Si(1). Following Gilbert and Hudgens
(2008), we define S to be an SoP if
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for some constant C ≥ 0. In words, S is an SoP if the vaccine has no average effect on survival
in groups of individuals who would have no immune response under vaccine and has some
average effect in groups of individuals who would have an immune response greater than C
under vaccine. Let p(z, s) denote the transmission probability conditional on Si(1) = s and Z =
z, such that E{Ti(z)|Si(1) = s} = 1/p(z, s). Then S is an SoP if
(2)
Therefore, whether S is an SoP can be evaluated through inference about the transmission
probability curves p(0, s) and p(1, s).
In practice, a biomarker may have value as a surrogate even if (2) is not strictly satisfied. For
example, if p(0, 0) is approximately equal to p(1, 0) while p(0, s) is substantially greater than
p(1, s) for s > C, then S is predictive of the vaccine’s effect on risk of infection. Therefore, to
summarize the predictiveness or “surrogate value” of a biomarker, Gilbert and Hudgens
(2008) proposed the proportion associative effect statistic PAE ≡ |EAE|/(|EAE| + |EDE|) where
and
are the expected associative and dissociative effects, and FS is the CDF of Si(1). Values of
PAE ≤ 0.5 suggest a biomarker has no surrogate value, while biomarkers with some surrogate
value will have PAE ∈ (0.5, 1]. The convention |0|/(|0|+|0|) = 0.5 is used to allow for the special
case where EAE = 0 and EDE = 0. Note PAE = 1 if and only if EDE = 0 and EAE ≠ 0, which
occurs when (2) holds and Pr[Si(1) > C] > 0. In other words, PAE attains the upper bound of
1 when Si(1) is an SoP.
Following Follmann (2006), we model the transmission probability by
(3)
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where Φ is the standard normal CDF, Wi is some baseline covariate that is correlated with
Si(1), and β ≡ (β1, …, β5). Under this model, S will be an SoP if β2 = 0 and β4 ≠ = 0. Setting h
(x, y) = Φ−1(1/y) − Φ−1(1/x) yields
(4)
where κ ≡ E{Si(1)|Si(1) > 0}/Pr[Si(1) > 0]. Letting FW denote the CDF of Wi, the two curves
p(z, s; β) ≡ ∫ p(z, s, w; β)dFW (w) for z = 0, 1 also inform about the surrogate value of S, with
larger |β4| and smaller |β2| reflecting greater surrogate value.
For subject i, let Ti ≡ min{Ti(0)(1−Zi)+Ti(1)Zi, Ci} denote the observed number of exposures
during the experiment where Ci denotes the right censoring time, i.e., the maximum allowable
number of exposures. Let δi equal 1 (0) if subject i is infected (uninfected) by the end of the
study and let Si ≡ Si(0)(1 − Zi) + Si(1)Zi denote the observed immune response. Suppose we
observe n iid copies of Oi ≡ (Zi, Ti, δi, Si, Wi). Letting G(s|W) be the conditional distribution
of Si(1) given Wi, the conditional likelihood is  where
and ϕ(Z, S, W, T, δ; β) ≡ {1 − p(Z, S, W; β)}T−δp(Z, S, W; β)δ.
Maximum “estimated likelihood” (Pepe and Fleming 1991) or “pseudolikelihood” (Liang and
Self 1996) can be used for inference regarding β and PAE. As in Follmann (2006) and Gilbert
and Hudgens (2008), we assume (S(1), W) arise from a bivariate normal distribution with means
(μS, μW), variances ( ) and correlation ρ, with left censoring of values of S(1) or W below
0. We estimate ν ≡ (μS, μW, , ρ) and hence G using {(Si, Wi):Zi = 1} and {Wi:Zi = 0}.
Conditional on Ĝ, the maximum estimated likelihood estimator (MELE) β ̂ is obtained by
maximizing log{L(β, Ĝ)} with respect to β. The estimator  is computed by evaluating (4)
at ν̂, β ̂. The bootstrap is used to estimate the standard errors of the estimators. A parametric
bootstrap test (Davison and Hinkely 1997) is employed to assess H0:PAE = 0.5 versus
HA:PAE > 0.5, i.e., to test the null S has no surrogate value versus the alternative S has some
surrogate value. To conduct the parametric bootstrap test (PBT), B samples of size n are
randomly sampled from the fitted null model using ν̂ and β ̂0, the MELE of β under H0. For
each sample, PAE is estimated and a one-sided test of size α is then conducted by comparing
 with the (1 − α) × 100th percentile of the B bootstrap estimates of PAE.
3.2 Simulation study
A simulation study was conducted to assess whether sample sizes typical of RLD challenge
studies provide adequate power to detect immune responses with high surrogate value. Data
were generated assuming: m NHPs per arm; a maximum number of exposures per NHP of
Ci = 30 for all i; an average probability of infection per exposure for controls of p(0) = 0.5; a
leaky vaccine effect with VES=0.8; and model (3). Values of (Si(1), Wi) were generated by
randomly sampling from a bivariate normal with μS = μW = 0.5, , and ρ = 0.5, 0.7
or 0.9. Values of Si(1) or Wi below 0 were set equal to 0. Under this parameterization,
approximately 10% of vaccinated animals have no (or undetectable) immune response. To
reffect immune responses with varying surrogate values, simulated data sets were generated
under three scenarios. For the first scenario, β = (.38, −.33, −.63, −4.57, −.1) such that PAE =
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0.9. Values for β for the remaining two scenarios were chosen such that PAE = 0.5 or 0.7, with
p(1, Si(1), Wi; β) the same as in the first scenario. For each scenario, 500 simulated data sets
were generated. For each simulated data set, the MELEs β ̂ and  were computed, their
standard errors were estimated, and the PBT of H0:PAE = 0.5 was conducted at the α = 0.1
significance level.
Simulation results are given in Table 3 and Figure 3. The MELE  is positively biased when
PAE = 0.5 or 0.7 and negatively biased when PAE = 0.9, although the magnitude of the bias
is negligible for m > 10. Likewise, the estimated transmission probability curves p(0, s; β ̂) and
p(1, s; β ̂) exhibit minimal bias. The PBT has approximately the nominal size overall and
adequate power for the high surrogate value scenario (i.e., PAE = 0.9) when there are 20 NHPs
per arm. For each combination of PAE, ρ, and m in Table 3, we also estimated the power to
detect a CoR, i.e., an association between Si(1) and Ti(1), based on fitting a probit model to
simulated data from the vaccine arm only. For all scenarios considered, the power to detect a
CoR was at least 0.97, demonstrating that larger studies are needed to detect an immune marker
with high surrogate value than to detect a CoR.
4 Discussion
Despite limited sample size, RLD challenge studies can inform about a vaccine’s mechanism
of protection and magnitude of effect. In particular, using discrete time survival models, we
show that maximum likelihood methods can afford accurate and precise estimates of vaccine
efficacy. While determining a vaccine’s mechanism of protection is difficult in human studies,
our results demonstrate that careful experimental design of challenge studies can lead to correct
determination of the type of mechanism. We also consider a generalization of these models
that allows for heterogeneous transmission probabilities. Similar extensions could easily be
made to incorporate baseline covariates or allow for the possibility that a subset of NHPs are
naturally immune to infection.
Our results also indicate it is possible to reliably evaluate potential immune SoPs in this setting.
Properly designed RLD challenge studies can be adequately power to detect CoRs, and, to a
lesser extent, immunological biomarkers with high surrogate value. These studies can also
yield accurate estimates of surrogate value, based on the estimated transmission probability
curves or functionals thereof such as PAE. However, results from our simulation study should
be interpreted with caution for several reasons. First, 20 NHPs per arm are needed to have
sufficient power to detect an immune marker with high surrogate value. Although such sample
sizes are not the norm in this setting, several RLD challenge studies at least this large are being
planned or conducted presently (John Mascola, personal communication). Second, the model
assumed by the SoP analysis was correct, which in practice will rarely if ever be the case
(discussed further below). Third, the assumed correlation of at least 0.5 between the HIV
vaccine immune response Si(1) and the baseline predictor Wi may or may not be realistic. There
are human studies of vaccines suggesting correlations of this magnitude may be realistic. For
example, a study that vaccinated 75 individuals simultaneously with hepatitis A and B vaccines
showed a linear correlation of 0.85 among A-specific and B-specific antibody titers
(Czeschinski, Binding, and Witting, 2000), demonstrating that Wi = hepatitis A titer may be
an excellent baseline predictor for Si(1) = hepatitis B titer, and vice versa. Further data are
needed from NHPs on realistic assumptions about the joint distribution of Si(1) and Wi to
calibrate additional simulation studies of power to detect immune responses with high surrogate
value.
The proposed approach to evaluating possible SoPs entails assuming SUTVA, ignorable
treatment assignment, and a parametric regression model for the transmission probabilities. As
discussed in Section 3.1, these first two assumptions should hold in RLD challenge studies.
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The appropriateness of the probit model (3) will be more difficult to assess without additional
information on Si(1). Some elaborations in the design of RLD challenge studies might be
helpful in this regard. For example, in addition to the baseline predictor design studied in
Section 3, Follman (2006) also proposed a second design, “closeout placebo vaccination” or
CPV. Using this approach, controls who remain uninfected by the end of study would receive
the HIV vaccine and their subsequent immune response would be measured. In the RLD
challenge study setting, CPV may not be feasible since most, if not all, control animals are
often infected after repeated challenges, e.g., see Subbarao et al. (2006) and Ellenberger et al.
(2006). If this scenario is anticipated, a possible variation on the CPV design would be to
vaccinate those NHPs randomized to the control arm that remain uninfected after a specific
number of exposures. Further research is needed on applying CPV and variations therein to
the RLD challenge setting.
We caution that the scope of inference drawn regarding the surrogate value of candidate specific
SoPs should be limited to settings similar to the study at hand. A single RLD challenge study
typically will not provide sufficient information for extrapolation to different vaccine
formulations or human populations. Such inferences generally require conduct of additional
studies. We refer the reader to Gilbert and Hudgens (2008) and Qin et al. (2007) for further
related discussion of SoP assessment in vaccine studies.
In contrast to SoPs, smaller RLD challenge studies can provide adequate power to detect a
CoR. For example, in our simulation study with 10 NHPs per arm, there was at most 50%
power to detect a SoP with high surrogate value, whereas the power to detect a CoR was greater
than 95%. In addition to requiring fewer NHPs, evaluation of potential CoRs does not require
obtaining a baseline covariate W correlated with S(1). These results are in concert with the
well-known principle in the surrogate endpoint literature that establishing a valid surrogate
requires substantially more evidence than merely determining a correlate.
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Left panel: Nonparametric (solid line) and parametric (dotted line) estimates of the survival
functions based on data from Ellenberger et al. (2006) and fitted leaky vaccine model from
Table 1. Right panel: Nonparametric estimates of the complementary log-log survival
functions.
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Difference in nonparametric estimates of the complementary log-log survival functions
between the vaccine and control arms for the observed data (bold lines) and 25 simulated data
sets (gray lines) for each of the four different mechanism of protection models.
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Results from simulation study described in Section 3.2 with m = 20 NHPs per arm. Solid lines
denote the true transmission probability curves p(z, s; β) for z = 0 (upper line) and z = 1 (lower
line). Dotted lines depict the mean of the estimated curves p(z, s; β ̂) over 500 simulated data
sets.
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